No link found between IVF and ovarian cancer

According to a large population study in Denmark, presented at the European Society of Human Reproduction and Embryology meeting, there is no association between ovarian cancer and hormonal stimulation of the ovaries to assist reproduction.Medical Xpress
Source: Society for Endocrinology - Category: Endocrinology Source Type: news

Related Links:

When it comes to anti-cancer drugs, it’s not only their effectiveness at killing the intended target that we want to know, but also their ability to reach and penetrate the cancer cells. Knowing whether the drug actually enters cancer cells can...
Source: Medgadget - Category: Medical Devices Authors: Tags: Genetics Materials Oncology Source Type: blogs
No increased risk of corpus uteri, invasive breast cancer for women undergoing assisted reproduction
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Journal, Source Type: news
TUESDAY, July 17, 2018 -- For women undergoing assisted reproduction, there is no increased risk of corpus uteri or invasive breast cancer, but there is an increased risk of ovarian cancer and in situ breast cancer, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma Interventions:   Biological: Anetumab Ravtansine; ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Ovarian Cancer Intervention:   Drug: Apatinib mesylate Sponsor:   First Affiliated Hospital of Harbin Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma Interventions:   Biological: Anetumab Ravtansine; ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Ovarian Cancer Intervention:   Drug: Apatinib mesylate Sponsor:   First Affiliated Hospital of Harbin Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Johnson&Johnson says it will "pursue all available appellate remedies" to reverse a St. Louis court verdict that awarded $4.7 billion to women who alleged that using the company ’s baby powder caused their ovarian cancer.  In a prepared statement, J&J (NYSE:JNJ) contends that the lawsuit filed on behalf of 22 women should not have been heard in Missouri because many of the women were not from the state.   Company spokeswoman Carol Goodrich predicted a reversal, saying, “The multiple errors…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
Johnson&Johnson was ordered to pay $4.7 billion to 22 women and their families who say the company's talcum powder contributed to their ovarian cancer. The New Brunswick, New Jersey-based company (NYS: JNJ) has faced charges that its talc-based products contain asbestos. The trial was brought forward by women who contend that J&J-branded baby powder contained the cancer-causing substance dating back at least to the 1970s. They also contend that J&J knew its talc was contaminated but failed to …
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Ovarian cancer has no definitive second line therapeutic options, and largely recurs in the peritoneal cavity. Locoregional immune therapy using both interferons and monocytes can be used as a novel approach. ...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Protocol Source Type: research
More News: Cancer | Cancer & Oncology | Denmark Health | Endocrinology | Hormones | Ovarian Cancer | Ovaries | Reproduction Medicine | Study